# EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

Study · id `cardio:ct-nct01435031` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01435031](<https://clinicaltrials.gov/study/NCT01435031>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01435031

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT01435031. Allocation not applicable; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2014-11-25.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT01435031, source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01435031, source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)
- Primary completion: 2014-02 (actual) (ClinicalTrials.gov record NCT01435031, source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)
- Completion: 2017-12 (actual) (ClinicalTrials.gov record NCT01435031, source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)
- Results first posted: 2014-11-25 (ClinicalTrials.gov record NCT01435031, source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01435031, source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01435031-2018-05-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
- Acronym: EXPERT CTO
- Condition: Coronary Artery Disease (CAD)
- Condition: Chronic Total Occlusion (CTO)
- Intervention (Device): CTO Treatment Device
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 9709f8a08e9daf02146ac4035f43b19fbc1c1d0f024f1c40e85349e3819c9185
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
